Mochida Pharmaceutical (4534) Fundamentals 2026 — P/E 14.1x, Revenue Analysis | SniperIQ
Mochida Pharmaceutical (4534) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥111.0B, trading at ¥3140.00 on the JPX. This SniperIQ fundamentals page covers Mochida Pharmaceutical's valuation (P/E 14.1x, P/B 0.8x), profitability (net margin 6.8%), revenue (¥117.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mochida Pharmaceutical's market cap?
Mochida Pharmaceutical (4534) has a market capitalization of approximately ¥111.0B, trading at ¥3140.00 on the JPX. Market cap moves with the live share price.
What is Mochida Pharmaceutical's P/E ratio?
Mochida Pharmaceutical's trailing twelve-month P/E ratio is 14.1x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mochida Pharmaceutical?
Mochida Pharmaceutical runs a net profit margin of 6.8%, a gross margin of 48.1%, and an operating margin of 8.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mochida Pharmaceutical generate?
Mochida Pharmaceutical reported revenue of ¥117.0B for fiscal year 2025, with net income of ¥7.9B and earnings per share (EPS) of 222.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mochida Pharmaceutical pay a dividend?
Mochida Pharmaceutical offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mochida Pharmaceutical financially healthy?
Mochida Pharmaceutical carries a debt-to-equity ratio of 0.07x and a current ratio of 4.29x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mochida Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mochida Pharmaceutical (4534) the key facts are: market cap ¥111.0B, P/E 14.1x, revenue ¥117.0B, 52-week range 2929-3965. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mochida Pharmaceutical's full fundamentals live
Get Mochida Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.